Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Israel

Sun Pharma Plans Hostile Takeover Of Taro

July 2008 | Company News Alert

Following the rejection of its merger agreement with Israel-based drug manufacturer Taro Pharma , India's Sun Pharma has launched a hostile takeover bid.

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Related Insight Articles
PIC/S Membership Edges Closer

Companies / Israel Israel is close to joining the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme (PIC/S), following a successful check of pharmaceutical manufacturing standards in...
August 2008
Pharmaceutical Exports Up 44% in Q2

Companies / Israel According to Globes [online], a survey by the Manufacturers Association of Israel reported that pharmaceutical exports grew by 44% in Q208 from Q1. The survey also showed that the pharmaceutical and...
July 2008
Mylan Eyes Generic Version Of Copaxone

Companies / Israel US-based Mylan has signed an agreement with India's NATCO Pharma to market a generic version of Israeli drugmaker Teva's multiple sclerosis drug Copaxone (glatiramer) in the US, Europe, Australia, New...
June 2008
Sun Ups Stake In Taro

Companies / Israel In a move that BMI interprets as a signal that India's Sun Pharmaceutical Industries is growing impatient with opposition to its proposed acquisition of Israel's Taro Pharmaceutical Industries from some...
February 2008
Teva Signals Pause In Acquisitions Quest

Companies / Israel Teva has also received final approval for Azilect (rasagiline), its proprietary drug for Parkinson's disease, from the US FDA. European and Israeli regulators approved the drug in 2005, and large-scale...
May 2006
Middle East & Africa InsightMiddle East & Africa Channels Middle East & Africa Countries


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2008 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS